All Pharma News
price-trendAsk Us
Takeda eyes $3B from emerging-market asset cull

Takeda eyes $3B from emerging-market asset cull
Angius Liu FIERCE PHARMA
22 Jan 2019
Share Share
In the midst of an R&D shift, Takeda inks $790M cancer collab with Crescendo

In the midst of an R&D shift, Takeda inks $790M cancer collab with Crescendo
Ben Adams FIERCE BIOTECH
11 Oct 2016
Share Share
Indian patents controller grants patent to Amgen for its ANTI-GM-CSF MAB

Indian patents controller grants patent to Amgen for its ANTI-GM-CSF MAB
TWOFOURINSIGHT
29 Dec 2015
Share Share